Another sparse round of NASH data; TG raises $60M after PhIII success

? The laboring NASH field added a new but sparse round of data this morning, with Axcella releasing results from a small non-IND enabled study on a pair of drugs. The study randomized 102 participants to placebo different doses of one?of two Axcella drugs, AXA1125 or AXA1957. Of the AXA1957 arm, 39% had a reduction in liver fat of over 30%, compared to 8% for the placebo arm. The results add another bit of data for a field that has seen its share of large-scale failures over the last year and is largely waiting for the much-delayed Phase III readout from Genfit, which is now expected to come later this month.

? One day after declaring a victory in their Phase III pivotal trial chronic lymphoblastic leukemia, TG Therapeutics announced they have raised $60 million to continue the development of their two lead drugs, ublituximab and umbralisib. Around $40 million came from longtime investor RA Capital.

? Merck announced positive Phase III results for Recarbrio, their antibiotic cocktail ? accepted for sNDA review by the FDA in hospital-acquired or ventilator-associated pneumonia in February. The results from the 537-person study showed non-inferiority to piperacillin and tazobactam the activity for 28-day all-cause mortality and clinical response.

Click to view original post